Clinical Trials Detalhe
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
Visão Geral
Gender
ALL
Idade
N/A
Fase
N/D
Tipo de Estudo
OBSERVATIONAL
Localização
Many Locations, Portugal
Clinicaltrial.gov
https://classic.clinicaltrials.gov/ct2/show/NCT00812175Sumário
In this international non-interventional study safety and clinical data concerning the treatment of patients suffering from Hepatocellular Carcinoma (HCC) will be collected.
Condições
Carcinoma, Hepatocellular
Elegibilidade
Inclusion Criteria: * Outpatients with histologically/cytologically documented or radiographically diagnosed unresectable HCC who are candidates for systemic therapy and for whom a decision to treat with Nexavar has been made. Radiographic diagnosis HCC NIS, needs typical findings of HCC by radiographic method i.e. on multi-dimensional, dynamic CT, CT hepatic arteriography (CTHA)/CT arterial portography (CTAP), or MRI. * Patients must have signed an informed consent form * Patients must have a life expectancy of at least 8 weeks Exclusion Criteria: * Exclusion criteria must follow the approved local product information